New COPD drug tested across chinese, japanese, and european volunteers
NCT ID NCT06979518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a single dose of the experimental drug GSK3862995B in 30 healthy adults of Chinese, Japanese, and European ancestry. The goal was to see if the drug is processed similarly across these groups, so that future global COPD studies can include diverse participants. Researchers monitored safety, side effects, and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GSK3862995B
- What this could lead to
- If successful, this study could help include Chinese and Japanese participants in future global trials for chronic obstructive pulmonary disease treatments.
- What could go wrong
- This is an early phase 1 safety study with only 30 healthy people, so it cannot yet show if the drug works for COPD. Results may not apply to patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
30 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant must be 18 to 50 years of age inclusive * Participants who are generally healthy as determined by medical evaluation based on screening medical history, physical examination, laboratory tests, and cardiac monitoring * Body weight of at least 50.0 kilogram (kg) for male participants or at least 45.0 kg for female participants * Body mass index (BMI) within the range of 18.0 to 28.0 kilogram per square meter (kg/m\^2) (inclusive) * Capable of giving signed informed consent * Males and females of non-childbearing potential• Exclusion Criteria: * History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data * A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug * Abnormal blood pressure (as determined by the investigator) * Symptomatic herpes zoster within 3 months prior to screening * Significant allergies to humanized monoclonal antibodies * Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions * Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years * Breast cancer within the past 10 years * Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) * A clinically significant abnormality in the average of triplicate 12-lead ECG readings performed at screening including * Antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal therapy within 30 days of dosing * Past or intended use of over the counter or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation * Live vaccine(s) within 30 days prior to screening or plans to receive such vaccines during the study * Treatment with biologic agents within 12 weeks, 5 half-lives or twice the duration of the biological effect of the biologic agent (whichever is longer) prior to dosing * Participation in other clinical study that resulted in loss of blood or blood products \>500 millilitres (mL) within a 56 days before participation in this study * Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day * Current enrolment or past participation in another investigational study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered prior to the first dosing day: 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer) * Current enrolment or past participation in this clinical study * A positive confirmation of SARS-CoV-2 infection at pre-dose * Evidence of active or latent Tuberculosis (TB) * Positive hepatitis Bor hepatitis C test at screening or within 3 months prior to study intervention. * Positive prestudy drug/alcohol test * An average weekly intake of \>14 units of alcohol * Regular use of known drugs of abuse, including Tetrahydrocannabinol (THC) * Current smoker or user or tobacco- or nictotine- containing products, within 30 days prior to screening visit * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study * Any products intended to treat medical conditions that are not approved by the governing health authority (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc) * The participant has a phobia to needles
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary disease, chronic obstructive are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Cypress, California, 90630, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.